Increased cathepsin D release by Hyp mouse osteoblast cells

American Journal of Physiology - Endocrinology and Metabolism

Volumn 289, Issue 1 52-1, 2005, Pages

  Matsumoto, Naoko ^b   Jo, Oak D ^b   Shih, Remi N J ^b   Brochmann, Elsa J ^b   Murray, Samuel S ^b   Hong, Victor ^b   Yanagawa, Jane ^b   Yanagawa, Norimoto ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Bone; Hypophosphatemia; Pepstatin; Rickets

Indexed keywords

CATHEPSIN D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIFICATION; CELL CULTURE; CELL DAMAGE; CELL POPULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEGRADATION; FEMALE; HYPOPHOSPHATEMIA; LABELING INDEX; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINASE INHIBITION; VITAMIN D RESISTANT RICKETS;

ANIMALS; CALCIUM; CATHEPSIN D; CELL LINE; HYPOPHOSPHATEMIA; MICE; MICE, INBRED C57BL; OSTEOBLASTS; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PROTEINS;

EID: 21044437394     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00562.2004     Document Type: Article

References (42)

1. Albright F, Butler AM, and Bloomberg E. Resistance to vitamin D therapy. Am J Dis Child 54: 529-547, 1937.
2. Andrews NW. Regulated secretion of conventional lysosomes. Trends Cell Biol 10: 316-321, 2000.
3. Bai X, Miao D, Panda D, Grady S, McKee MD, Goltzman D, and Karaplis AC. Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol 16: 2913-2925, 2002.
4. Berchem G, Glondu M, Gleizes M, Brouillet JP, Vignon F, Garcia M, and Liaudet-Coopman E. Cathepsin D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 21: 5951-5955, 2002.
5. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, and Kumar R. Secreted frizzled-related protein 4 is a potent tumor- derived phosphaturic agent. J Clin Invest 112: 785-794, 2003.
6. Blair HC. How the osteoclast degrades bone. Bioessays 20: 837-846, 1998.
7. Boileau G, Tenenhouse HS, Desgroseillers L, and Crine P. Characterization of PHEX endopeptidase catalytic activity: identification of para-thyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochem J 355: 707-713, 2001.
8. Bresler D, Bruder J, Mohnike KL, Fraser D, and Rowe PSN. Serum MEPE-ASARM peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets. J Endocrinol 183: R1-R9, 2004.
9. Capony F, Rougeot C, Montcourrier P, Cavailles V, Salazar G, and Rochefort H. Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res 49: 3904-3909, 1989.
10. Campos M, Couture C, Hirata IY, Juliano MA, Loisel TP, Crine P, Juliano L, Boileau G, and Carmona AK. Human recombinant endopeptidase PHEX has a strict S1′ specificity for acidic residues and cleaves peptides derived from fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein. Biochem J 373: 271-279, 2003.
11. Dubois SG, Ruchon AF, Delalandre A, Boileau G, and Lajeunesse D. Role of abnormal neutral endopeptidase-like activities in Hyp mouse bone cells in renal phosphate transport. Am J Physiol Cell Physiol 283: C1414-C1421, 2002.
12. Ecarot B, Glorieux FH, Desbarats M, Travers R, and Labelle L. Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect. J Bone Miner Res 7: 215-220, 1992.
13. Ecarot-Charrier B, Glorieux FH, Travers R, Desbarats M, Bouchard F, and Hinek A. Defective bone formation by transplanted Hyp mouse bone cells into normal mice. Endocrinology 123: 768-773, 1988.
14. Ecarot B, Glorieux FH, Desbarats M, Travers R, and Labelle L. Effect of 1,25-dihydroxyvitamin D3 treatment on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice. J Bone Miner Res 10: 424-431, 1995.
15. Eicher EM, Southard JL, Scriver CR, and Glorieux FH. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci USA 73: 4667-4671, 1976.
16. Fusek M and Vetvicka V. Mitogenic function of human procathepsin D: the role of the propeptide. Biochem J 303: 775-780, 1994.
17. Guo R, Rowe PS, Liu S, Simpson LG, Xiao ZS, and Darryl Quarles LD. Inhibition of MEPE cleavage by Phex. Biochem Biophys Res Commun 297: 38-45, 2002.
18. Isidoro C, Baccino FM, and Hasilik A. Mis-sorting of procathepsin D in metastogenic tumor cells is not due to impaired synthesis of the phosphomannosyl signal. Int J Cancer 70: 561-566, 1997.
19. Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, Tayback M, and Fisher LW. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 89: 4158-4161, 2004.
20. Kidd VJ, Lahti JM, and Teitz T. Proteolytic regulation of apoptosis. Semin Cell Dev Biol 11: 191-201, 2000.
21. Kornfeld S. Trafficking of lysosomal enzymes. FASEB J 1: 462-468, 1987.
22. Lenarcic B, Kos J, Dolenc I, Lucovnik P, Krizaj I, and Turk V. Cathepsin D inactivates cysteine proteinase inhibitors, cystatins. Biochem Biophys Res Commun 154: 765-772, 1988.
23. Liu S, Guo R, Tu Q, and Quarles LD. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem 277: 3686-3697, 2002.
24. Mathieu M, Vinon F, Capony F, and Rochefort H. Estradiol downregulates the mannose-6-phosphate/insulin-like growth factor-H receptor gene and induces cathepsin D in breast cancer cells: a receptor saturation mechanism to increase the secretion of lysosomal proenzymes. Mol Endocrinol 5: 815-822, 1991.
25. Matsumoto N, Jo O, Shih RN, and Yanagawa N. Role of cathepsin D in Hyp mouse bone defect (Abstract). J Am Soc Nephrol 14: 467A, 2003.
26. Miao D, Bai X, Panda D, McKee M, Karaplis A, and Goltzman D. Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition. Endocrinology 142: 926-939, 2001.
27. Miao D, Bai X, Panda DK, Karaplis AC, Goltzman D, and McKee MD. Cartilage abnormalities are associated with abnormal Phex expression and with altered matrix protein and MMP-9 localization in Hyp mice. Bone 34: 638-647, 2004.
28. Nishimura Y, Kawabata T, and Kato K. Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch Biochem Biophys 261: 64-71, 1988.
29. O'Farrell PH. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250: 4007-4021, 1975.
30. Queries LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285: E1-E9, 2003.
31. Ribari O and Sziklai I. Cathepsin D activity in otosclerotic bone and perilymph. Acta Otolaryngol (Stockh) 105: 549-552, 1988.
32. Rochefort H and Liaudet-Coopman E. Cathepsin D in cancer metastasis: a protease and a ligand. APMIS 107: 86-95, 1999.
33. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, and Oudet CL. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67: 54-68, 2000.
34. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Queries LD, and Mundy GR. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34: 303-319, 2004.
35. Rowe PSN, Garrett IR, Schwarz PM, Carnes DL, Lafer EM, Mundy GR, and Gutierrez GE. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP). Bone 36: 33-46, 2005.
36. Sedmak JJ and Grossberg SE. A rapid, sensitive, and versatile assay for protein using Coomassie brilliant blue G250. Anal Biochem 79: 544-552, 1977.
37. Shih NR, Jo OD, and Yanagawa N. Effects of PHEX antisense in human osteoblast cells. J Am Soc Nephrol 13: 394-399, 2002.
38. Tenenhouse HS. X-linked hypophosphataemia: a homologous disorder in humans and mice. Nephrol Dial Transplant 14: 333-341, 1999.
39. The Consortium. A gene (PEX) HYP with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11: 130-136, 1995.
40. Tsukuba T, Okamoto K, Yasuda Y, Morikawa W, Nakanishi H, and Yamamoto K. New functional aspects of cathepsin D and cathepsin E. Mol Cell 10: 601-611, 2000.
41. Wittlin S, Rosel J, Hofmann F, and Stover DR. Mechanisms and kinetics of procathepsin D activation. Eur J Biochem 265: 384-393, 1999.
42. Xiao ZS, Guo CR, Nesbitt T, Drezner MK, and Queries LD. Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol Endocrinol Metab 275: E700-E708, 1998.